Clinical trial
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
NCT00328276 · China Medical University Hospital, Other · Completed
Key facts
| NCT number | NCT00328276 |
|---|---|
| Title | Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia |
| Official title | NMDA Enhancers in the Treatment of Schizophrenia |
| Lead sponsor | China Medical University Hospital, Other |
| Collaborators | National Health Research Institutes, Taiwan National Science and Technology Council, Taiwan |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders |
| Intervention type | Drug |
| Interventions | Sarcosine |
| Enrollment | 20 |
| Start date | Dec 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | May 19, 2006 |
| Last update posted | May 19, 2006 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: